Join our Community
Support ToI and remove all ads
Learn more
×

molnupiravir

Merck's new antiviral medication molnupiravir. (Merck & Co. via AP, File)
September 25, 2023, 7:17 pm
New study suggests anti-COVID drug may be causing virus to mutate
Merck’s molnupiravir has been used in Israel and other countries since late 2021 to treat symptomatic patients with risk factors that could lead to hospitalization or death
By Renee Ghert-Zand
Merck antiviral medication molnupiravir. (Merck & Co. via AP, File)
January 2, 2022, 6:24 pm
Health Ministry approves Merck’s anti-COVID pill, the second okayed in Israel
First shipment expected to arrive in coming days; ministry doesn’t specify numbers or price but report says there will be enough for several thousand treatments at $700 a pop
By ToI Staff and Agencies
This undated image provided by Merck shows its new antiviral medication against COVID-19. (Merck via AP)
November 27, 2021, 12:35 am
Anti-COVID pill effective in treating virus, FDA panel’s report finds
Tablet developed by Merck known as molnupiravir found to halve rate of hospitalizations and deaths in high-risk Covid patients; not recommended for pregnant women
By AFP
This undated image provided by Merck shows its new antiviral medication against COVID-19. (Merck via AP)
November 4, 2021, 6:34 pm
UK authorizes first pill shown to treat COVID
Health secretary hails approval of Merck’s molnupiravir as a ‘historic day,’ says Britain looking to start national study on treatment ‘as soon as possible’
By MATTHEW PERRONE and Maria Cheng
This undated image provided by Merck & Co. shows its new antiviral medication (Merck & Co. via AP)
October 6, 2021, 11:46 am
Israel said working to get supply of breakthrough Merck COVID-19 antiviral pill
Bennett reportedly makes announcement to coronavirus cabinet; if cleared, molnupiravir would be 1st pill shown to treat coronavirus patients, a potentially major advance
By ToI Staff and AP
Load More
Sign in or Join The Times of Israel Community
Paying ToI Community members are invited to comment on articles
Please use the following structure: example@domain.com
Or Continue with
By joining you agree to the terms and conditions
Register to continue
Or Continue with
Log in to continue
Sign in or Join The Times of Israel Community
Only ToI Community members can comment below articles
Forgot your password? / Send me a login link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.
Join The Times of Israel Community
Commenting is available for paying members of The Times of Israel Community only. Please join our Community to comment and enjoy other Community benefits.
Please use the following structure: example@domain.com
Confirm Mail
Thank you! Now check your email
You are now a member of The Times of Israel Community! We sent you an email with a login link to . Once you're set up, you can start enjoying Community benefits and commenting.
Back to top
Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed
image
Register for free
and continue reading
Registering allows you to manage your newsletters and alerts and helps us improve your experience. It takes just a few seconds.
Already registered? Enter your email to sign in.
Please use the following structure: example@domain.com
Or Continue with
By registering you agree to the terms and conditions. Once registered, you’ll receive our Daily Edition email for free.
Register to continue
Or Continue with
Log in to continue
Sign in or Register
I forgot my password / Send me a sign in link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.